An enterococcal phage-derived enzyme suppresses graft-versus-host disease.
Kosuke Fujimoto, Tetsuya Hayashi, Mako Yamamoto...
https://pubmed.ncbi.nlm.nih.gov/38987594/Actively Recruiting
Led by First Affiliated Hospital of Zhejiang University · Updated on 2026-08-28
198
Participants Needed
1
Research Sites
15 weeks
Total Duration
Researchers are studying how different stomach protection methods affect the risk of acute graft-versus-host disease aGVHD in patients undergoing allogeneic hematopoietic stem cell transplantation allo-HSCT. This trial compares the routine use of proton pump inhibitors PPIs, which may change gut bacteria and increase aGVHD risk, with teprenone, a drug that protects the stomach lining without reducing stomach acid. The study aims to see if switching from PPIs to teprenone after transplantation lowers aGVHD rates and related complications. Participants are randomly assigned to one of two groups one group receives standard-dose PPIs during conditioning and switches to teprenone after transplant through day 100 the other group continues PPIs from conditioning through day 100. Probiotics are not allowed during this period. Both groups receive the same anti-infective and graft-versus-host disease prevention treatments alongside their assigned stomach protection therapy. During the study, participants will follow their assigned stomach protection treatment and undergo regular checks for safety and effectiveness, including monitoring for aGVHD and infections. They will provide stool, saliva, and blood samples at several points before and after transplantation to analyze gut and oral microbiomes and other biological markers. Participants will be followed for one year to assess health outcomes, including aGVHD incidence, infections, and survival.
CONDITIONS
GMPA Versus PPI for Gastric Protection and aGVHD Risk
F
Fei Gao
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
First Affiliated Hospital of Zhejiang University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - From conditioning through day +100 post-transplantation
Participants receive either continuous proton pump inhibitors or switch to teprenone after transplantation through day +100 as assigned.
Duration - Up to 1 year post-transplantation
Participants are monitored for safety, effectiveness, and health outcomes including acute graft-versus-host disease and infections for up to one year after transplantation.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kosuke Fujimoto, Tetsuya Hayashi, Mako Yamamoto...
https://pubmed.ncbi.nlm.nih.gov/38987594/Xian Zhang, Qing Li, Siyuan Xia...
https://pubmed.ncbi.nlm.nih.gov/39457584/Eiko Hayase, Tomo Hayase, Mohamed A Jamal...
https://pubmed.ncbi.nlm.nih.gov/36179667/Xue Xiao, Xian Zhang, Jin Wang...
https://pubmed.ncbi.nlm.nih.gov/38267200/Chi L Nguyen, Jennifer Funes, Romina Ghale...
https://pubmed.ncbi.nlm.nih.gov/41460962/Jiaying Zhu, Chuqing Sun, Min Li...
https://pubmed.ncbi.nlm.nih.gov/38050061/Yannouck F van Lier, Jaël Vos, Bianca Blom...
https://pubmed.ncbi.nlm.nih.gov/36794370/Floris Imhann, Arnau Vich Vila, Marc Jan Bonder...
https://pubmed.ncbi.nlm.nih.gov/28118083/C K Stein-Thoeringer, K B Nichols, A Lazrak...
https://pubmed.ncbi.nlm.nih.gov/31780560/Olaf Penack, Monia Marchetti, Mahmoud Aljurf...
https://pubmed.ncbi.nlm.nih.gov/38184001/First Affiliated Hospital of Zhejiang University
Lead Sponsor